RF Bio, RF Tech Subsidiary, Begins PN Filler Clinical Trials... Accelerates Cosmetics Expansion into Europe

RF Bio, the bio subsidiary of RF Tech, announced on July 8 that it has officially begun exploratory clinical trials for its PN filler. The company is also accelerating its entry into the global market by expanding the European CPNP (Cosmetic Product Notification Portal) certification for its cosmetics products.

Through this clinical trial, the company aims to verify the efficacy and safety of the PN filler in improving crow's feet wrinkles. Last month, together with Promedis, a contract research organization with which it has signed a consignment agreement, the company submitted a request for exploratory clinical review to the Institutional Review Board (IRB) at Inje University Sanggye Paik Hospital. The clinical trial is scheduled for completion in the first quarter of 2026, after which the company plans to begin pivotal trials within 2026.

RF Bio is developing products that deliver rapid effects and safety by applying high-concentration, high-dose PN (polynucleotide), a medical device ingredient with wrinkle improvement and anti-inflammatory effects. The company stated that, through this clinical trial, it aims to strengthen its competitiveness in the aesthetic medical device market with a differentiated PN filler product.

Alongside the PN filler, the company is expanding its functional cosmetics lineup and actively pursuing entry into the European market. Recently, it signed a consulting agreement with the Korea Testing & Research Institute (KTR) to promote the expansion of European CPNP certification. In January 2024, the "Youth Heal" brand's "Skin Booster" product received European CPNP approval, and additional registrations for subsequent products are underway. The company stated its plan to enhance long-term brand value and overseas competitiveness by securing global certifications.

Youth Heal Skin Booster is a total care skin booster whose main ingredients are plant-derived exosomes extracted from ginseng and broccoli, along with dual (sturgeon and salmon) PDRN. PDRN is a DNA component that promotes the regeneration of damaged skin tissue. Recently, the product has been experiencing continuous sales growth not only in Europe but also in countries such as Japan, Russia, and Saudi Arabia.

RF Bio's strategy is to diversify its business portfolio by expanding R&D investment and global expansion in both the medical device and cosmetics sectors. In addition, following the recent termination of a contract to change the largest shareholder, the company plans to focus on internal organizational restructuring and management stabilization.